Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01138644 · ClinicalTrials.gov registry record

Atrial Fibrillation/Flutter Outcome Risk Determination

A clinical trial of Atrial Fibrillation and Atrial Flutter, sponsored by Vanderbilt University.

Completed
Registry status
519
Enrollment target
1
Study location

NCT01138644: Completed study of Atrial Fibrillation and Atrial Flutter, sponsored by Vanderbilt University.

NCT01138644 is a study of Atrial Fibrillation and Atrial Flutter that has completed, run by Vanderbilt University. The registered enrollment target is 519 participants, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01138644, a study of Atrial Fibrillation and Atrial Flutter, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
519 participants
Enrollment target
1
Study location

Study Summary

It is our hypotheses that 1) readily available Emergency Department data can be utilized in an Atrial Fibrillation clinical prediction rule to identify those patients at low or high risk for adverse outcomes; 2) Assigned risk can be utilized to drive physician decision-making by identifying patients who do not require hospital admission (low risk) and patients needing hospitalization (high risk); and 3) a facile version of the AFPR will be easily incorporated into standard Emergency Department patient management systems and assist physicians with risk stratification of patients presenting with Atrial Fibrillation.

Primary Outcome

We define adverse events as the following patient death, 5-day ED return visits and unscheduled hospital admissions for AF-related complaints, AF-related cardiovascular and thromboembolic complications.

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Emergency Medicine - Nashville

Trial Details

FieldValue
Enrollment Target 519 participants
Start Date 2010-06
Est. Completion 2015-04
Vanderbilt University

430 total trials

What the finished NCT01138644 record still lists

NCT01138644 is an observational study that tracks outcomes without assigning an intervention. The registered 519 participants enrollment target is mid-sized for trials with a published cap, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (83% lower).

The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 0 interventions.

NCT01138644 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT01138644 about?

NCT01138644 is a clinical study titled "Atrial Fibrillation/Flutter Outcome Risk Determination". It is our hypotheses that 1) readily available Emergency Department data can be utilized in an Atrial Fibrillation clinical prediction rule to identify those patients at low or high risk for adverse outcomes; 2) Assigned risk can be utilized to drive physician decision-making by identifying patients...

What is the current status of trial NCT01138644?

This trial is currently completed. The enrollment target is 519 participants. The study started on 2010-06. Estimated completion is 2015-04.

What conditions does trial NCT01138644 study?

This clinical trial studies the following conditions: Atrial Fibrillation, Atrial Flutter.

Who is sponsoring clinical trial NCT01138644?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01138644 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01138644's enrollment target sits among peer trials

519 58th of 202 higher than 145 of 202 other Atrial Fibrillation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02323581 · 520 participants · NA

    Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts

  • NCT04656496 · 520 participants · NA

    NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors

  • NCT05445778 · 520 participants · Phase 3

    Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

  • NCT05498428 · 520 participants · Phase 2

    A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01138644, the US trial registry maintained by the National Library of Medicine. NCT01138644 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.